Nuveen’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-220,114
| Closed | -$8.86M | – | 3743 |
|
|
2026
Q1 | $8.86M | Sell |
220,114
-461,705
| -68% | -$9.95M | ﹤0.01% | 1626 |
|
|
2025
Q4 | $17.1M | Buy |
681,819
+16,771
| +3% | +$393K | ﹤0.01% | 1231 |
|
|
2025
Q3 | $15.1M | Buy |
665,048
+195,795
| +42% | +$4.57M | ﹤0.01% | 1316 |
|
|
2025
Q2 | $8.12M | Sell |
469,253
-22,985
| -5% | -$425K | ﹤0.01% | 1638 |
|
|
2025
Q1 | $10.8M | Buy |
492,238
+1,131
| +0.2% | +$31.2K | ﹤0.01% | 1513 |
|
|
2024
Q4 | $15.7M | Buy |
491,107
+150,384
| +44% | +$4.52M | ﹤0.01% | 1320 |
|
|
2024
Q3 | $9.83M | Buy |
340,723
+60,722
| +22% | +$2.25M | ﹤0.01% | 1624 |
|
|
2024
Q2 | $10.7M | Buy |
280,001
+9,425
| +3% | +$427K | ﹤0.01% | 1536 |
|
|
2024
Q1 | $15.9M | Buy |
270,576
+56
| +0% | +$3.57K | ﹤0.01% | 1313 |
|
|
2023
Q4 | $16.2M | Sell |
270,520
-2,993
| -1% | -$152K | 0.01% | 1293 |
|
|
2023
Q3 | $10.4M | Buy |
273,513
+11,115
| +4% | +$488K | ﹤0.01% | 1461 |
|
|
2023
Q2 | $23.9M | Sell |
262,398
-87,156
| -25% | -$7.52M | 0.01% | 966 |
|
|
2023
Q1 | $23.1M | Sell |
349,554
-11,181
| -3% | -$645K | 0.01% | 950 |
|
|
2022
Q4 | $18.7M | Sell |
360,735
-49,666
| -12% | -$2.63M | 0.01% | 1089 |
|
|
2022
Q3 | $28M | Buy |
410,401
+34,201
| +9% | +$2.02M | 0.01% | 805 |
|
|
2022
Q2 | $17M | Buy |
376,200
+112,555
| +43% | +$5.13M | 0.01% | 1158 |
|
|
2022
Q1 | $13.7M | Buy |
263,645
+7,204
| +3% | +$318K | ﹤0.01% | 1436 |
|
|
2021
Q4 | $10.8M | Sell |
256,441
-9,803
| -4% | -$386K | ﹤0.01% | 1643 |
|
|
2021
Q3 | $9.11M | Sell |
266,244
-64,935
| -20% | -$3.65M | ﹤0.01% | 1843 |
|
|
2021
Q2 | $20.9M | Buy |
331,179
+67,218
| +25% | +$3.47M | 0.01% | 1330 |
|
|
2021
Q1 | $11.3M | Sell |
263,961
-4,455
| -2% | -$211K | ﹤0.01% | 1723 |
|
|
2020
Q4 | $15.4M | Sell |
268,416
-4,131
| -2% | -$175K | 0.01% | 1419 |
|
|
2020
Q3 | $8.22M | Buy |
272,547
+212
| +0.1% | +$6.33K | ﹤0.01% | 1633 |
|
|
2020
Q2 | $8.89M | Sell |
272,335
-88,470
| -25% | -$2.84M | ﹤0.01% | 1555 |
|
|
2020
Q1 | $9.67M | Buy |
360,805
+166,194
| +85% | +$5.9M | ﹤0.01% | 1311 |
|
|
2019
Q4 | $5.96M | Sell |
194,611
-20
| -0% | -$554 | ﹤0.01% | 1889 |
|
|
2019
Q3 | $4.69M | Buy |
194,631
+22,503
| +13% | +$619K | ﹤0.01% | 1991 |
|
|
2019
Q2 | $4.36M | Buy |
+172,128
| New | +$3.5M | ﹤0.01% | 2064 |
|
Other funds holding APLS
Nuveen's APLS Position: Q2 2026 in Review
Nuveen sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 220,114 shares — an estimated $8.86M sold.
Nuveen first reported a position in APLS in Q2 2019 and held it in 28 quarters. The position peaked at $28M in Q3 2022. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Nuveen reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Nuveen sold 220,114 Apellis Pharmaceuticals shares in Q2 2026, an estimated $8.86M.
- Nuveen first reported a position in Apellis Pharmaceuticals in Q2 2019 and held it in 28 quarters.
- Nuveen's Apellis Pharmaceuticals position peaked at $28M in Q3 2022.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.